Back to Journals » Vascular Health and Risk Management » Volume 8

Critical evaluation of the efficacy and tolerability of azilsartan

Authors De Caterina AR, Harper AR, Cuculi F

Received 9 March 2012

Accepted for publication 10 April 2012

Published 14 May 2012 Volume 2012:8 Pages 299—305

DOI https://doi.org/10.2147/VHRM.S22589

Review by Single-blind

Peer reviewer comments 4

Alberto R De Caterina1,2, Andrew R Harper2,3, Florim Cuculi2

1Istituto Scienze della Vita, Scuola Superiore Sant'Anna, Pisa, Italy; 2Oxford University Hospitals, Oxford; 3Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom

Abstract: Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.

Keywords: azilsartan medoxomil, angiotensin receptor blocker, hypertension

Corrigendum for this paper has been pubilshed.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Corrigendum

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

Readers of this article also read:

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus

Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA

Vascular Health and Risk Management 2015, 11:35-48

Published Date: 6 January 2015

Visceral obesity is not an independent risk factor of mortality in subjects over 65 years

Thomas F, Pannier B, Benetos A, Vischer UM

Vascular Health and Risk Management 2013, 9:739-745

Published Date: 22 November 2013

Statins in heart failure: do we need another trial?

Bonsu KO, Kadirvelu A, Reidpath DD

Vascular Health and Risk Management 2013, 9:303-319

Published Date: 17 June 2013

Predictors of poor blood pressure control assessed by 24 hour monitoring in patients with type B acute aortic dissection

Delsart P, Midulla M, Sobocinski J, Achere C, Haulon S, Claisse G, Mounier-Vehier C

Vascular Health and Risk Management 2012, 8:23-30

Published Date: 10 January 2012

Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications

Carlos V Serrano Jr, Karina Tiemi Setani, Erica Sakamoto, et al

Vascular Health and Risk Management 2011, 7:159-164

Published Date: 16 March 2011

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Giuseppe Camporese, Enrico Bernardi, Franco Noventa

Vascular Health and Risk Management 2009, 5:819-831

Published Date: 25 September 2009